4D Molecular Therapeutics (FDMT) Short-term Investments (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Short-term Investments of $318.4 million for Q1 2026, up 69.44% year-over-year from $187.9 million in Q1 2025, and down 7.01% quarter-over-quarter from $342.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Short-term Investments (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Short-term Investments for 6 consecutive years, with $318.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments rose 69.44% year-over-year to $318.4 million; the TTM figure through Mar 2026 stood at $318.4 million (up 69.44% YoY), while the FY2025 annual figure was $342.4 million, up 24.27% from the prior year.
- Short-term Investments slipped to $318.4 million in Q1 2026 per FDMT's latest filing, from $342.4 million in the prior quarter.
- Across five years, Short-term Investments topped out at $352.9 million in Q2 2024 and bottomed at $39.1 million in Q4 2023.
- Historically, Short-term Investments has averaged $197.8 million across 5 years, with a median of $187.9 million in 2025.
- Annual changes were most pronounced in 2023 — Short-term Investments plunged 75.73% — and 2024, when it soared 614.67%.
- 4D Molecular Therapeutics' Short-term Investments stood at $161.2 million in 2022, then slumped by 75.73% to $39.1 million in 2023, then surged by 604.28% to $275.5 million in 2024, then rose by 24.27% to $342.4 million in 2025, then decreased by 7.01% to $318.4 million in 2026.
- Business Quant data shows FDMT's Short-term Investments at $318.4 million in Q1 2026, $342.4 million in Q4 2025, and $256.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 290.96 Mn |
| Mar 31, 2026 | 318.40 Mn |
| Dec 31, 2025 | 342.41 Mn |
| Sep 30, 2025 | 256.51 Mn |
| Jun 30, 2025 | 216.07 Mn |
| Mar 31, 2025 | 187.91 Mn |
| Dec 31, 2024 | 275.54 Mn |
| Sep 30, 2024 | 314.35 Mn |
| Jun 30, 2024 | 352.89 Mn |
| Mar 31, 2024 | 250.32 Mn |
| Dec 31, 2023 | 39.12 Mn |
| Sep 30, 2023 | 43.99 Mn |
| Jun 30, 2023 | 74.03 Mn |
| Mar 31, 2023 | 121.89 Mn |
| Dec 31, 2022 | 161.20 Mn |
| Sep 30, 2022 | 119.42 Mn |
| Jun 30, 2022 | 127.60 Mn |
| Mar 31, 2022 | 160.18 Mn |
| Dec 31, 2021 | 94.78 Mn |
| Sep 30, 2021 | 70.69 Mn |